Aurora Cannabis Makes Medical Cannabis More Accessible for Patients in Australia

Enhancing Patient Access to Medical Cannabis in Australia

In a bold move to facilitate patient access to medical cannabis in Australia, Aurora Cannabis Inc., a prominent player in the global medical cannabis landscape, has recently announced the elimination of concession card requirements for its IndiMed brand products. This strategic decision is poised to significantly enhance access for patients needing high-quality medical cannabis options.

Since its inception in Australia in 2021, IndiMed has become a cornerstone of accessibility in the medical cannabis sector, previously requiring a concession card for patients to access its offerings. With the recent adjustments, patients now have a seamless pathway to obtain prescriptions for IndiMed products, thus expanding treatment options and supporting prescribers in their efforts to meet patient needs.

Andre Jerome, the Executive Vice President of Global Business Development at Aurora, stated, "This change to open up patient access to MedReleaf's IndiMed products reflects our dedication to supporting prescribers by creating more seamless and simplified prescribing options." This statement underscores the company's commitment to removing obstacles in the medical cannabis arena.

Notably, IndiMed’s product lineup has evolved over time, progressing from a singular offering to a diverse range, including oils, dried flowers, and resin cartridges. The current popularity of IndiMed flower products is evidenced by their consistent ranking among the top 10 most prescribed cannabis options for patients. Such statistics speak volumes about the trust patients and healthcare providers have placed in the quality and efficacy of IndiMed’s products.

Aurora Cannabis operates through its wholly-owned subsidiary, MedReleaf Australia, which proudly meets all Therapeutic Goods Administration-Good Manufacturing Practice (TGA-GMP) standards, ensuring that every product is manufactured to the highest quality. This dedication to quality assurance is vital, considering that patients often rely on cannabis for therapeutic and medical benefits.

Those interested in learning more about the company's offerings can reach out to MedReleaf Australia’s clinical support team or explore their website at www.medreleafaustralia.com.au.

In addition to this groundbreaking policy change, Aurora has filed a final short form base shelf prospectus with securities regulators throughout Canadian provinces, with the exception of Quebec, and a corresponding shelf registration statement with the United States Securities and Exchange Commission. This move signals the company's readiness to expand its operations further and invest in new opportunities.

Aurora Cannabis Inc. is at the forefront of the global cannabis movement, with a focus on both medical and consumer markets. Based in Edmonton, Alberta, the company serves various regions, including Canada, Europe, Australia, and South America. Its diversified portfolio encompasses numerous brands such as Drift, San Rafael '71, and Tasty's, alongside medical cannabis lines such as CanniMed and Whistler Medical Marijuana Co.

As Aurora continues to navigate the complexities of the cannabis sector, its proactive measures to remove eligibility barriers showcase its adaptability and commitment to patient care in an ever-growing field. By enhancing accessibility, Aurora not only sets a standard within the industry but also underscores its mission: to improve lives through the power of cannabis.

In essence, Aurora Cannabis Inc.'s recent changes significantly contribute to improving patient access to essential medical products, reinforcing its leading role in the cannabis landscape. As the company moves forward, it remains committed to innovation and quality, ensuring that patients can access the treatment options they need. This development marks a promising future for the Australian medical cannabis market and the patients it serves, as we witness the evolution of marijuana treatment fosters and nurtures enhanced healthcare models.